Yoga for lung functions in COVID-19 survivors
- Conditions
- Coronavirus as the cause of diseases classified elsewhere,
- Registration Number
- CTRI/2021/09/036829
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Coronavirus disease recovered cases reveal the varying degrees of radiological abnormalities associated with the deterioration of the pulmonary function which could manifest in a cascade of cardiopulmonary consequences and abnormal lung function. Also, unprecedented change, fear, and uncertainty during the COVID era has implicated in emotional distress, psychosocial dysfunction, and a surge of mental health problems. Yoga improvement in pulmonary function, rehabilitation, Health-Related Quality of Life and reduces Anxiety & Depression, several types of research have demonstrated the benefits of yoga. The current study attempts to explore yoga-based rehabilitation using a validated and customized yoga module. Keeping this in consideration, a randomized controlled open-label, endpoint blind, a clinical trial is planned to evaluate Yoga therapy as an add-on to standard care in Post covid patients.The proposed study design is a prospective randomized open label blinded endpoint trial with 1:1 allocation ratio. The study participant may fall into the intervention arm will give Yoga for 30 mint for 12 weeks.outcome measures on Baseline, after 6 weeks and at the end of 12 weeks of study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 104
a)Known case of COVID patients with respiratory symptoms on screening (RT-PCR negative or 4 weeks to 8 weeks from the onset of first symptom) b)Patients with forced vital capacity(FVC)<80% c)Patients of both sex and age of18-75years d)Patients who are able and willing to practice any form of exercise when recruited under the study e)Patients who are not engaged in regular and structured yoga practice.
- a)Patients with forced vital capacity FVC<40 % b)Previous pulmonary complications like severe asthma, COPD, bronchiectasis, interstitial lung disease(IL) c)Known cases of CAD with moderate to severe LV dysfunction, patients with a history of CV or neurodegenerative diseases.
- d)Lactating and pregnant women.
- e)Patients currently participating in any other clinical trials with intervention.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulmonary Function: Diffusion lung capacity for carbon monoxide (DLCO), Forced Vital capacity (FVC), Forced expiratory volume in first second (FEV1), Total lung capacity (TLC) using Pulmonary function test Baseline, after 6 weeks and at the end of 12 weeks
- Secondary Outcome Measures
Name Time Method Severity of dyspnea using UCSD Shortness of Breath Questionnaire. Exercise capacity using 6-minute walk test
Trial Locations
- Locations (1)
All India Institute of Medical Science
🇮🇳Delhi, DELHI, India
All India Institute of Medical Science🇮🇳Delhi, DELHI, IndiaDr Randeep GuleriaPrincipal investigator9911110487randeepguleria2002@yahoo.com
